{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+sc+%28single-dose%29", "query": { "intervention": "Placebo sc (single-dose)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 334, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+sc+%28single-dose%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T22:22:18.463Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04142424", "title": "A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metabolic Disorders", "Non-alcoholic Steatohepatitis" ], "interventions": [ { "name": "AZD2693", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 73, "start_date": "2019-10-28", "completion_date": "2021-11-12", "has_results": false, "last_update_posted_date": "2021-11-26", "last_synced_at": "2026-09-24T22:22:18.463Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04142424" }, { "nct_id": "NCT07305818", "title": "NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graves Disease" ], "interventions": [ { "name": "MER511 (IV)", "type": "BIOLOGICAL" }, { "name": "Placebo comparator (IV)", "type": "BIOLOGICAL" }, { "name": "MER511 (SC)", "type": "BIOLOGICAL" }, { "name": "Placebo comparator (SC)", "type": "BIOLOGICAL" }, { "name": "MER511 (SC) for MAD", "type": "BIOLOGICAL" }, { "name": "Placebo comparator (SC) for MAD", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merida Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 100, "start_date": "2025-12-19", "completion_date": "2028-07-24", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-24T22:22:18.463Z", "location_count": 11, "location_summary": "Torrance, California • Hollywood, Florida • Miami, Florida + 8 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Wesley Chapel", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07305818" }, { "nct_id": "NCT02759107", "title": "A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Type 2 Diabetes Mellitus (T2DM)" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dulaglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 142, "start_date": "2016-05-11", "completion_date": "2017-06-26", "has_results": true, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-09-24T22:22:18.463Z", "location_count": 1, "location_summary": "South Miami, Florida", "locations": [ { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02759107" }, { "nct_id": "NCT06354660", "title": "Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Type 2" ], "interventions": [ { "name": "Retatrutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 537, "start_date": "2024-04-10", "completion_date": "2026-02-20", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-24T22:22:18.463Z", "location_count": 29, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Canoga Park, California + 25 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Fleming Island", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06354660" }, { "nct_id": "NCT01162889", "title": "Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Placebo SC Injection", "type": "DRUG" }, { "name": "ATR-107 (PF-05230900) SC Injection", "type": "DRUG" }, { "name": "ATR-107 (PF-05230900) IV Infusion", "type": "DRUG" }, { "name": "Placebo IV Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 70, "start_date": "2010-06", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-09-24T22:22:18.463Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Overland Park, Kansas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01162889" }, { "nct_id": "NCT07090785", "title": "A Study of LY4088044 in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LY4088044", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 104, "start_date": "2025-07-24", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-09-24T22:22:18.463Z", "location_count": 4, "location_summary": "Los Alamitos, California • Lenexa, Kansas • San Antonio, Texas + 1 more", "locations": [ { "city": "Los Alamitos", "state": "California" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07090785" }, { "nct_id": "NCT00963885", "title": "A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "RO5190591 (Danoprevir)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2009-08", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-24T22:22:18.463Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00963885" }, { "nct_id": "NCT00440362", "title": "A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "AVX502", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AlphaVax, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 216, "start_date": "2007-04", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2008-11-10", "last_synced_at": "2026-09-24T22:22:18.463Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00440362" }, { "nct_id": "NCT02595736", "title": "A Study of LY3200327 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Placebo (SC)", "type": "DRUG" }, { "name": "LY3200327 (SC)", "type": "DRUG" }, { "name": "LY3200327 (IV)", "type": "DRUG" }, { "name": "Placebo (IV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 52, "start_date": "2015-11", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2016-09-12", "last_synced_at": "2026-09-24T22:22:18.463Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02595736" }, { "nct_id": "NCT04184622", "title": "A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Overweight", "Obesity" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2539, "start_date": "2019-12-04", "completion_date": "2024-07-06", "has_results": true, "last_update_posted_date": "2025-07-24", "last_synced_at": "2026-09-24T22:22:18.463Z", "location_count": 54, "location_summary": "Pelham, Alabama • Scottsdale, Arizona • Concord, California + 47 more", "locations": [ { "city": "Pelham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04184622" } ] }